Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer

BACKGROUND: The safety and immunogenicity of JNJ-64041809 (JNJ-809), a live-attenuated, double-deleted Listeria monocytogenes (LADD Lm)-based immunotherapy targeting 4 relevant prostate cancer antigens, was evaluated in a phase 1 study in patients with metastatic castration-resistant prostate cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Drake, Charles G., Pachynski, Russell K., Subudhi, Sumit K., McNeel, Douglas G., Antonarakis, Emmanuel S., Bauer, Todd M., Lauer, Peter, Brockstedt, Dirk, Patricia, Daniel, Wade, Mark, Zudaire, Enrique, Bandyopadhyay, Nibedita, Parasrampuria, Dolly A., Girgis, Suzette, Mason, Gary E., Knoblauch, Roland E., Stone, Nicole, Infante, Jeffrey R., Gottardis, Marco M., Fong, Lawrence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184270/
https://www.ncbi.nlm.nih.gov/pubmed/34257408
http://dx.doi.org/10.1038/s41391-021-00402-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184270/
https://www.ncbi.nlm.nih.gov/pubmed/34257408
http://dx.doi.org/10.1038/s41391-021-00402-8

Ejemplares similares